Regeneron Pharmaceuticals (REGN) EBT Margin (2009 - 2026)

Regeneron Pharmaceuticals has reported EBT Margin for 18 years, with the latest figure at 35.61% in Q2 2026.

• On a quarterly basis, EBT Margin fell 571.0% year-over-year to 35.61% in Q2 2026; TTM through Jun 2026 was 33.25%, a 104.0% decrease from a year earlier, with the FY2025 full-year figure at 36.47%, up 281.0% from the prior year.
• EBT Margin was 35.61% for Q2 2026 at Regeneron Pharmaceuticals, up from 23.05% in the prior quarter.
• The five-year high for EBT Margin was 1324.7% in Q4 2022, with the low at 22.28% in Q1 2024.
• Average EBT Margin over 5 years is 106.15%, with a median of 34.0% recorded in 2022.
• The sharpest annual moves came in 2022 and 2023: EBT Margin jumped 127414 bps in 2022, then plunged 129128 bps in 2023.
• Over 5 years, EBT Margin stood at 1324.7% in 2022, then sank by 97 bps to 33.42% in 2023, then declined by 24 bps to 25.29% in 2024, then gained by 6 bps to 26.87% in 2025, then soared by 33 bps to 35.61% in 2026.
• The last three EBT Margin figures came in at 35.61% (Q2 2026), 23.05% (Q1 2026), and 26.87% (Q4 2025), per Business Quant data.